Early Career Investigator Award for Ataxia Research

Deadline: 18-Nov-2026

The National Ataxia Foundation Early Career Investigator Award provides $50,000 for a one-year research project addressing the causes, mechanisms, diagnosis, or treatment of ataxia. Early-stage scientists in the United States and other countries must submit a Letter of Intent by 18 November 2026, with invited full proposals considered for funding decisions in June 2027.

About the Early Career Investigator Award

The Early Career Investigator Award supports outstanding early-stage scientists developing independent research careers in ataxia. The program provides short-term funding for innovative studies capable of generating pilot data, testing new ideas, and supporting future external grant applications.

Research may address:

- Hereditary ataxias - Sporadic ataxias - Acquired ataxias

About the National Ataxia Foundation

The National Ataxia Foundation is a patient-centered nonprofit organization dedicated to accelerating treatment development and improving the lives of people affected by ataxia.

NAF promotes collaboration among:

- Researchers - Clinicians - Universities - Research organizations - Biotechnology and pharmaceutical companies - Patients and families - National and international scientific networks Its research programs support scientific discovery, treatment development, diagnostic innovation, and researcher career development. Purpose of the Grant The award is intended to help promising scientists establish independent research programs and make meaningful contributions to ataxia science.

Its objectives include:

- Supporting innovative early-stage research - Generating pilot and preliminary data - Advancing understanding of disease mechanisms - Developing and validating disease models - Identifying therapeutic targets - Exploring new treatment strategies - Preparing researchers for larger external grants - Strengthening long-term commitment to ataxia research - Supporting the transition to research independence - Improving future diagnosis, treatment, and patient outcomes What Is Ataxia? Ataxia is a neurological condition characterized by impaired coordination, balance, speech, movement, or control of voluntary muscles.

It may be:

- Hereditary: Caused by inherited or genetic factors

- Sporadic: Occurring without a clear family history

- Acquired: Resulting from injury, illness, immune processes, toxins, nutritional deficiencies, or other factors

Ataxia can significantly affect mobility, communication, independence, and quality of life. Priority Research Areas

Priority is given to projects addressing:

- Fundamental disease mechanisms - Ataxia pathogenesis - Development of disease models - Validation of disease models - Emerging therapeutic targets - Innovative treatment strategies - Biomarker research - Diagnostic approaches - Early-stage data collection - Clinical-trial readiness - Translational research - Patient-related research Projects should address a significant scientific gap and demonstrate potential to advance the field. Fundamental Disease Mechanisms Research may investigate how ataxia begins, develops, or progresses.

Potential topics include:

- Genetic pathways - Cellular dysfunction - Molecular signaling - Protein accumulation - Neurodegeneration - Cerebellar biology - Immune mechanisms - Disease progression - Relationships between biological processes and symptoms Applicants should explain how improved mechanistic knowledge could inform diagnosis, treatment, or future research. Disease Model Development Disease models help researchers understand ataxia and test potential treatments.

Projects may involve:

- Cellular models - Animal models - Patient-derived models - Organoid systems - Computational models - Genetic models - Validation of existing experimental systems - Comparison of models with human disease Applications should explain why the model is needed and how it will improve upon existing approaches. Therapeutic Targets and Strategies Research may investigate new ways to prevent, slow, modify, or treat ataxia.

Projects may include:

- Target identification - Target validation - Drug screening - Drug repurposing - Gene-based approaches - Molecular therapies - Cellular interventions - Preclinical treatment studies - Treatment-response markers - Early translational research Applicants should provide a realistic explanation of the project’s position within the therapeutic-development process. Preliminary Data Generation The award is particularly useful for collecting evidence required to compete for larger grants.

Pilot data may support:

- Feasibility - Validation of methods - Future research hypotheses - Larger sample-size studies - Therapeutic-development programs - Clinical studies - Independent grant applications - New collaborations The proposal should explain how the resulting data will strengthen future research. Funding Amount and Duration

The award provides:

- Total funding: $50,000

- Project duration: One year

- Funding type: Direct research expenses only

- Letter of Intent deadline: 18 November 2026

- Funding decisions: June 2027

The project should have focused aims that can be completed within the one-year grant period. Eligible Research Expenses

The award may support:

- Salary or stipend - Laboratory reagents - Consumable research supplies - Essential equipment - Animal purchase and care - Publication costs - Scientific meeting registration - Travel to scientific meetings - Patient-related research expenses - Other approved direct costs Every expense must be necessary for the proposed study and adequately justified. Budget Limits

The following limits apply:

- Salary or stipend: Up to $25,000

- Essential equipment: Up to 20% of the total budget

- Publication expenses: Up to $2,500

- Scientific meeting registration and travel: Up to $2,000 For a $50,000 award, essential equipment costs may not exceed $10,000. Patient-Related Expenses Patient-related expenses may be included when directly connected to the study. Potential costs ma